Devimistat receives FDA Fast Track Designation for pancreatic cancer

Devimistat is a first-in-class agent which targets the mitochondrial tricarboxylic acid cycle, a process essential to tumour cell multiplication and survival. It is also being investigated in acute myeloid leukaemia, myelodysplastic syndrome and sarcoma.

Source:

Biospace Inc.